注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Clearside Biomedical Inc是一家生物制药公司。该公司专注于通过脉络膜上腔(SCS)为患有严重眼后部疾病患者开发和提供治疗方法。其SCS注射平台利用其SCS显微注射器,实现办公室内可重复的非手术程序,用于有针对性地向黄斑、视网膜或脉络膜提供各种治疗,以保持和改善视力威胁眼部疾病患者的视力。它专注于开发自己的小分子候选产品,通过其SCS微注射器给药。它还与开发其他眼科治疗药物的公司合作,使用其SCS注射平台进行给药。其主要候选产品XIPERE是一种不含防腐剂的皮质类固醇曲安奈德(TA)混悬剂,通过脉络膜注射给药。其产品线包括CLS-AX、CLS-301和Gene Therapy。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Christy L. Shaffer | 65 | 2012 | Independent Director |
Richard J. Croarkin | 69 | 2016 | Independent Director |
Jeffrey L. Edwards | 62 | 2018 | Independent Director |
Clay Bernardin Thorp | 55 | 2012 | Independent Chair of the Board |
Carl D. Regillo | - | 2020 | Member of Scientific Advisory Board |
Nancy June Hutson | 74 | 2020 | Independent Director |
David M. Brown | - | 2020 | Member of Scientific Advisory Board |
David S. Boyer | - | 2020 | Member of Scientific Advisory Board |
Arshad M. Khanani | - | 2023 | Member of Scientific Advisory Board |
Lejla Vajzovic | - | 2023 | Member of Scientific Advisory Board |
Thomas A. Ciulla | 59 | 2018 | Chairman of Scientific Advisory Board |
Anthony S. Gibney | 53 | 2024 | Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核